TY - JOUR
T1 - Protection against rotavirus disease after natural rotavirus infection
AU - for the US Rotavirus Vaccine Efficacy Group
AU - Ward, Richard L.
AU - Bernstein, David I.
AU - Cherry, J.
AU - Kim, K.
AU - Maldonado, Y.
AU - Froehlich, H.
AU - Levin, M.
AU - Fries, S.
AU - Chartrand, S.
AU - Pomeranz, A.
AU - Jackson, H.
AU - Anderson, E.
AU - Harnm, C.
AU - Bernstein, D.
AU - Ward, R.
AU - James, N.
AU - Imrie, R.
AU - Wald, E.
AU - Pickering, L.
AU - Van Dyke, R.
AU - Rodgers, G.
AU - Glass, R.
AU - Pichichero, M.
AU - Singh-Naz, N.
AU - Sack, D.
AU - Rennels, M.
AU - Dennehy, P.
PY - 1994/4
Y1 - 1994/4
N2 - Determination of protective efficacy after natural rotavirus infection is important as a basis for evaluating rotavirus vaccines. Therefore, placebo recipients in a large 2-year rotavirus vaccine trial conducted across the United States were followed to determine the protection afforded by natural rotavirus infection. Serotype 1 rotaviruses predominated (93% year 1, 66% year 2), but isolates of all four majorhuman rotavirus serotypes circulated during both years. Of the 45 placebo recipients with documented rotavirus illnesses in year 1, 1 developed rotavirus disease in year 2 compared with 29 of the other 235 placebo recipients (P =.03). Serologic data were available for 171 placebo recipients, and 37 of 140 without rotavirus illnesses in year 1 had evidence of asymptomatic rotavirus infection. None of these 37 experienced rotavirus disease in year 2 compared with 22 ofthe remaining 103 (P <.001). Overall efficacy after natural rotavirus infection was 93% (95% confidence interval, 50%-99%).
AB - Determination of protective efficacy after natural rotavirus infection is important as a basis for evaluating rotavirus vaccines. Therefore, placebo recipients in a large 2-year rotavirus vaccine trial conducted across the United States were followed to determine the protection afforded by natural rotavirus infection. Serotype 1 rotaviruses predominated (93% year 1, 66% year 2), but isolates of all four majorhuman rotavirus serotypes circulated during both years. Of the 45 placebo recipients with documented rotavirus illnesses in year 1, 1 developed rotavirus disease in year 2 compared with 29 of the other 235 placebo recipients (P =.03). Serologic data were available for 171 placebo recipients, and 37 of 140 without rotavirus illnesses in year 1 had evidence of asymptomatic rotavirus infection. None of these 37 experienced rotavirus disease in year 2 compared with 22 ofthe remaining 103 (P <.001). Overall efficacy after natural rotavirus infection was 93% (95% confidence interval, 50%-99%).
UR - http://www.scopus.com/inward/record.url?scp=0028325241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028325241&partnerID=8YFLogxK
U2 - 10.1093/infdis/169.4.900
DO - 10.1093/infdis/169.4.900
M3 - Article
C2 - 8133107
AN - SCOPUS:0028325241
SN - 0022-1899
VL - 169
SP - 900
EP - 904
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -